Episode Details
Back to Episodes
Jefferies London: Zymeworks had double-news during London Life Science Week - a P3 success for its HER2 bispecific in gastroesophageal cancer and it also launched a new royalty model
Published 9 months, 4 weeks ago
Description
CEO Kenneth Galbraith explains the new dual business focus and walks us through the topline HER2 data.